Data on 84,622 type 2 diabetes patients showed those on exogenous insulin treatment had a higher risk of complications -- including major cardiovascular events, renal conditions, cancer and all-cause mortality -- than those who were on other glucose-lowering therapies. "There is a clear need to review the way in which exogenous insulin is used in people with type 2 diabetes and to establish in detail the risk-benefit profile at differing stages of the natural history of the disease and in phenotypically different subgroups," researchers wrote in the Journal of Clinical Endocrinology and Metabolism.

Related Summaries